Last reviewed · How we verify
Ezharmia (VALEMETOSTAT)
Ezharmia (generic name: VALEMETOSTAT) is a Small molecule drug developed by Daiichi Sankyo. It is currently FDA-approved for Relapsed or refractory T-cell leukemia-lymphoma.
Ezharmia, also known as Valemetostat Tosylate, is a small molecule. It is a compound with the synonyms Valemetostat Tosylate and Valemetostat Tosilate.
At a glance
| Generic name | VALEMETOSTAT |
|---|---|
| Sponsor | Daiichi Sankyo |
| Target | Histone-lysine N-methyltransferase EZH2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Relapsed or refractory T-cell leukemia-lymphoma
Common side effects
Key clinical trials
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (PHASE1,PHASE2)
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (PHASE2)
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (PHASE1,PHASE2)
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma (PHASE2)
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (PHASE1)
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors (PHASE1)
- Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer (PHASE1)
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ezharmia CI brief — competitive landscape report
- Ezharmia updates RSS · CI watch RSS
- Daiichi Sankyo portfolio CI
Frequently asked questions about Ezharmia
What is Ezharmia?
What is Ezharmia used for?
Who makes Ezharmia?
What is the generic name of Ezharmia?
What development phase is Ezharmia in?
What does Ezharmia target?
Related
- Target: All drugs targeting Histone-lysine N-methyltransferase EZH2
- Manufacturer: Daiichi Sankyo — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory T-cell leukemia-lymphoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing